Loading patent…
AssigneeSecarna Pharmaceuticals GmbH & Co. KG
InventorsFrank Jaschinski, Richard Klar, Sven Michel, Julia Festag
Estimating the term…
The present invention refers to an oligonucleotide comprising 12 to 25 nucleotides, wherein at least one of the nucleotides comprises a modification selected from the group consisting of a bridged nucleic acid such as LNA, ENA, a 2′Fluoro modified nucleotide, a 2 O-Methyl modified nucleotide, a 2 O-Methoxy modified nucleotide, a FANA and a combination thereof. The oligonucleotide hybridizes with a nucleic acid sequence of Foxp3 of SEQ ID NO. 1 and/or of SEQ ID NO. 2 resulting in a reduction of the expression of FoxP3 mRNA, FoxP3 pre-mRNA or a combination thereof. The invention is further directed to a pharmaceutical composition comprising an oligonucleotide of the present invention and to the oligonucleotide and pharmaceutical composition, respectively for use in a method of preventing and/or treating a disorder, where FoxP3 imbalance is involved.
An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:81, wherein at least one of the nucleotides comprises a modification selected from the group consisting of LNA (locked nucleic acid), ENA (2′-O,4′-C-ethylene-bridged nucleic acid), a 2′-fluoro modified nucleotide, a 2-O-methyl modified nucleotide, a 2-O-methoxy modified nucleotide, a FANA (2′-deoxy-2-fluoro-D-arabinonucleic acid), and a combination thereof, and hybridizing with a nucleic acid sequence of Foxp3 of SEQ ID NO. 1 and/or of SEQ ID NO. 2 resulting in a reduction of FoxP3, FoxP3 mRNA, FoxP3 pre-mRNA or a combination thereof of 40% to 99% within 6 to 240 h or within 12 to 120 h from first administration of the oligonucleotide compared to an untreated control.
Dependencies are inferred from the claim text.